Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 11, 2026

Bank of America makes bold call on bank stocks

View original at finance.yahoo.com
Bank of America makes bold call on bank stocks Bank of America Securities starts 2026 with a strong message: Bank stocks can beat the S&P 500 again…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Citigroup ROTCE will improve by about 300 bps from 2025 to 2027, with path toward low-teens ROTCE long-term

    80% confidence
  • Citigroup EPS will expand by around 25% on average each year from FY26 to FY27

    80% confidence
  • Current conditions are more similar to the late 1990s and early 2000s than post-global financial crisis period

    80% confidence
  • Wells Fargo removal of asset cap allows pursuit of better growth and higher productivity, leading to eventual re-rating

    80% confidence
  • Without a recession, BofA doesn't expect a huge credit cycle or much improvement in credit quality

    80% confidence
  • Expects strong M&A and IPO activity due to strategic investor and sponsor interest and smooth approval process

    80% confidence
  • Morgan Stanley ROTCE could rise into the low to mid-20s over time if synergies and capital deployment succeed

    80% confidence
  • Focus on GSIBs with significant capital markets business; only buy regionals that can show growth and operating leverage

    80% confidence
  • Rate stability is more crucial than cuts; positively sloped yield curve and lower rate volatility improve net interest margins

    80% confidence
  • Citigroup has the best risk/reward among large-cap banks

    80% confidence
  • Wells Fargo stocks could perform better in second half of 2026 versus first half

    80% confidence
  • Morgan Stanley is hard to replicate due to strong U.S. wealth business and global capital markets platform

    80% confidence
  • AI won't have a big effect on bank profits in 2026, though it may become a more expensive long-term driver

    80% confidence
  • Wells Fargo ROTCE will reach about 17% by 2027, rising toward 18% in 2028

    80% confidence
  • Expects additional bank mergers and acquisitions, especially regional banks seeking growth and deposits

    80% confidence
  • Bank stock outperformance is part of a multi-year run driven by deregulation, better capital-markets cycle, rising domestic capex, and stable credit quality

    80% confidence
  • Goldman Sachs EPS growth will accelerate to about 19% for FY26 compared to about 14% for FY25

    80% confidence
  • Bank stocks can beat the S&P 500 again in 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Bank of America makes bold call on bank stocks — Source | Via News | Finance Via News